Sentinel lymph node biopsy and melanoma: 2010 update : Part I - 24/04/13
, Lilit Garibyan, MD, PhD, Arthur J. Sober, MD
Reprint requests: William G. Stebbins, MD, Massachusetts General Hospital, Department of Dermatology, 55 Fruit St, Bartlett Hall 616, Boston, MA 02114.Abstract |
Sentinel lymph node biopsy for melanoma was introduced in the early 1990s as a minimally invasive method of identifying and pathologically staging regional lymph node basins in patients with clinical stage I/II melanoma. Numerous large trials have demonstrated that sentinel lymph node evaluation has utility in improving accuracy of prognostication and for risk stratifying patients into appropriate groups for clinical trials. However, there remains a great deal of controversy regarding the therapeutic role of removal of the remainder of locoregional lymph nodes should metastatic cells be identified in the sentinel node. This CME article will outline a brief history of the sentinel node concept before reviewing updates in surgical technique, histopathologic evaluation of nodal tissue, and cost effectiveness of sentinel node biopsy.
Learning objectives |
After completing this learning activity, participants should be able to describe the concept of sentinel lymph node biopsy, to discuss the risks and benefits associated with this procedure, and to summarize the role of sentinel lymph node biopsy in management of patients with melanoma.
Le texte complet de cet article est disponible en PDF.Key words : melanoma, sentinel lymph node biopsy
Abbreviations used : ELND, HMB-45, IHC, MART-1, Melan-A, MSLT-1, RT-PCR, SLN, SLNB
Plan
| Drs Stebbins and Garibyan contributed equally to this work. |
|
| Funding sources: None. |
|
| Conflicts of interest: The authors, editors, and peer reviewers have no relevant financial relationships. |
Vol 62 - N° 5
P. 723-734 - mai 2010 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?